The DOI matches its Crossref record.
Colistin‐Tobramycin Combinations Are Superior to Monotherapy Concerning the Killing of Biofilm Pseudomonas aeruginosa
Abstract
BACKGROUND: Antibiotic combination therapy might be more efficient than single antibiotics to combat Pseudomonas aeruginosa biofilms in the airways of patients with cystic fibrosis. We tested the ability of colistin sulphate-tobramycin combinations and single antibiotics to kill P. aeruginosa biofilms. METHODS: P. aeruginosa biofilms were generated in vitro and in rat lungs. In a pilot study, 5 patients with cystic fibrosis inhaled colistin and then tobramycin for 4 weeks. The changes in P. aeruginosa counts and lung function were assessed before and after therapy. RESULTS: Antibiotic combination therapy significantly reduced the number of P. aeruginosa cells in P. aeruginosa biofilm models in vitro. When rats were challenged with 1 x 10(7) cfu of P. aeruginosa, which was embedded in alginate beads, mortality rates, lung pathologic findings, and bacterial colony-forming unit counts were significantly lower after 7 days in animals receiving antibiotic combination than in animals receiving single antibiotics. In patients with cystic fibrosis, inhaled colistin-tobramycin was well tolerated and resulted in a mean decrease of 2.52 + /- 2.5 log(10) cfu of P. aeruginosa per milliliter of sputum (P = .027). Measurements of forced expiratory volume in 1 s, obtained both before and after the study, did not differ significantly. CONCLUSION: Colistin-tobramycin combinations are more efficient than respective single antibiotics for killing P. aeruginosa in biofilms in vitro, and they significantly reduced P. aeruginosa cell counts in a rat lung infection model and in patients with cystic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Roy, R., Tiwari, M., Donelli, G., & Tiwari, V. (2018) · Virulence · doi:10.1080/21505594.2017.1313372 · Cited by 1,523
Strategies for combating bacterial biofilm infections
Wu, H., Moser, C., Wang, H.-Z., Høiby, N., & Song, Z.-J. (2015) · International Journal of Oral Science · doi:10.1038/ijos.2014.65 · Cited by 925
Self-citationThe clinical impact of bacterial biofilms
Høiby, N., Ciofu, O., Johansen, H. K., Song, Z., Moser, C., Jensen, P. Ø., Molin, S., Givskov, M., Tolker‐Nielsen, T., & Bjarnsholt, T. (2011) · International Journal of Oral Science · doi:10.4248/ijos11026 · Cited by 894
Self-citationCiofu, O., & Tolker-Nielsen, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00913 · Cited by 720
Applying insights from biofilm biology to drug development — can a new approach be developed?
Bjarnsholt, T., Ciofu, O., Molin, S., Givskov, M., & Høiby, N. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4000 · Cited by 516
Self-citation
Metadata
- Authors
- Herrmann, G., Yang, L., Wu, H., Song, Z., Wang, H., Høiby, N., Ulrich, M., Molin, S., Riethmüller, J., & Döring, G.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-15
- Volume
- 202
- Issue
- 10
- Pages
- 1585-1592
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2153511020
- Cited by
- 219
- References
- 0
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colistin‐Tobramycin Combinations Are Superior to Monotherapy Concerning the Killing of Biofilm Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.1086/656788
- The paper
- Herrmann, G., Yang, L., Wu, H., Song, Z., Wang, H., Høiby, N., Ulrich, M., Molin, S., Riethmüller, J., & Döring, G. (2010). Colistin‐Tobramycin Combinations Are Superior to Monotherapy Concerning the Killing of Biofilm Pseudomonas aeruginosa. The Journal of Infectious Diseases. https://doi.org/10.1086/656788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.